C
Cornelia Reininger
Researcher at Bayer Corporation
Publications - 65
Citations - 3181
Cornelia Reininger is an academic researcher from Bayer Corporation. The author has contributed to research in topics: Florbetaben & Platelet. The author has an hindex of 23, co-authored 65 publications receiving 2868 citations. Previous affiliations of Cornelia Reininger include Bayer HealthCare Pharmaceuticals & GE Healthcare.
Papers
More filters
Journal ArticleDOI
Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study
Ian G. McKeith,John T. O'Brien,Zuzana Walker,Klaus Tatsch,Jan Booij,Jacques Darcourt,Alessandro Padovani,Raffaele Giubbini,Ubaldo Bonuccelli,Duccio Volterrani,Clive Holmes,Paul Kemp,Naji Tabet,Ines Meyer,Cornelia Reininger +14 more
TL;DR: The findings confirm the high correlation between abnormal (low binding) DAT activity measured with (123)I-FP-CIT SPECT and a clinical diagnosis of probable DLB and the diagnostic accuracy is sufficiently high for this technique to be clinically useful in distinguishing DLB from Alzheimer's disease.
Journal ArticleDOI
Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study
Henryk Barthel,Hermann-Josef Gertz,Stefan Dresel,Oliver Peters,Peter Bartenstein,Katharina Buerger,Florian Hiemeyer,Sabine M Wittemer-Rump,John Seibyl,Cornelia Reininger,Osama Sabri +10 more
TL;DR: The diagnostic efficacy of the scans was established in differentiating between patients with probable disease and age-matched healthy controls on the basis of neocortical tracer uptake pattern 90-110 min post-injection and the sensitivity and specificity of florbetaben (¹⁸F) PET was assessed.
Journal ArticleDOI
Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study
Osama Sabri,Marwan N. Sabbagh,John Seibyl,Henryk Barthel,Hiroyasu Akatsu,Yasuomi Ouchi,Kohei Senda,Shigeo Murayama,Kenji Ishii,Masaki Takao,Thomas G. Beach,Christopher C. Rowe,James B. Leverenz,Bernardino Ghetti,James W. Ironside,Ana M. Catafau,Andrew W. Stephens,Andre Mueller,Norman Koglin,Anja Hoffmann,Katrin Roth,Cornelia Reininger,Walter J. Schulz-Schaeffer +22 more
TL;DR: Evaluation of brain β‐amyloid by positron emission tomography (PET) imaging can assist in the diagnosis of Alzheimer disease and other dementias.
Journal ArticleDOI
Amyloid Imaging with 18 F-Florbetaben in Alzheimer Disease and Other Dementias
Victor L. Villemagne,Kevin Ong,Rachel S. Mulligan,Gerhard Holl,Svetlana Pejoska,Gareth Jones,Graeme O'Keefe,Uwe Ackerman,Henri Tochon-Danguy,J. Gordon Chan,Cornelia Reininger,Lueder Fels,Barbara Putz,Beate Rohde,Colin L. Masters,Christopher C. Rowe +15 more
TL;DR: 18F-florbetaben had high sensitivity for AD, clearly distinguished patients with FTLD from AD, and provided results comparable to those reported with 11C-Pittsburgh Compound B in a variety of neurodegenerative diseases.
Journal ArticleDOI
Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT.
Vicky L. Marshall,Cornelia Reininger,Moritz Marquardt,Jim Patterson,Donald M. Hadley,Wolfgang H. Oertel,Hani T.S. Benamer,Paul Kemp,David J. Burn,Eduardo Tolosa,Jamie Kulisevsky,Luís Cunha,Durval C. Costa,Jan Booij,Klaus Tatsch,K. Ray Chaudhuri,Gudrun Ulm,Oliver Pogarell,Helmut Höffken,Anja Gerstner,Donald G. Grosset +20 more
TL;DR: On‐site clinical diagnosis overdiagnosed degenerative parkinsonism at baseline in diagnostically uncertain cases compared with the gold standard clinical diagnosis (at 36 months), the latter giving a sensitivity of 93% and specificity of 46%.